E-cadherin germline mutation carriers: clinical management and genetic implications

Area of Science:

• Genetics
• Oncology
• Gastroenterology

Background:

• Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant syndrome linked to E-cadherin (CDH1) gene mutations.
• CDH1 mutations are also associated with lobular breast cancer (LBC), a distinct neoplastic condition.
• International guidelines for HDGC genetic screening were updated in 2010.

Purpose of the Study:

• To review the clinical management of individuals with CDH1 germline mutations.
• To provide recommendations for genetic counseling, clinical criteria, surveillance, and prophylactic surgery in CDH1 mutation carriers.

Main Methods:

• Critical review of existing literature on CDH1 germline mutations and associated cancers.
• Analysis of clinical management strategies, including genetic counseling and surgical interventions.

Main Results:

• Approximately 40% of families meeting HDGC criteria have deleterious CDH1 mutations.
• Prophylactic total gastrectomy is the only life-saving procedure for HDGC carriers.
• No prophylactic mastectomies have been reported in CDH1 carriers, but new research suggests a need for re-evaluation.

Conclusions:

• Management of CDH1 mutation carriers requires a multidisciplinary approach.
• Genetic counseling is essential for informed decision-making regarding surveillance and prophylactic surgery.
• Emerging evidence necessitates a re-evaluation of management strategies for breast cancer risk in CDH1 carriers.